CancerDrs

Brain Cancer clinical trials in New Jersey

23 actively recruiting brain cancer trials at 18 sites across New Jersey.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Network

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in New Jersey:
  • Morristown Medical Center — Morristown, New Jersey
  • Newton Medical Center — Newton, New Jersey
  • Robert Wood Johnson University Hospital Somerset — Somerville, New Jersey
  • Overlook Hospital — Summit, New Jersey
  • Holy Name Hospital — Teaneck, New Jersey
Phase 3 Recruiting Academic/Other

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications …

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07215910
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
  • Hackensack University Medical Center — Hackensack, New Jersey
  • Memorial Sloan Kettering Monmouth — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen — Montvale, New Jersey
Phase 3 Recruiting NIH

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in New Jersey:
  • Morristown Medical Center — Morristown, New Jersey
Phase 3 Recruiting Network

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …

Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in New Jersey:
  • Saint Peter's University Hospital — New Brunswick, New Jersey
  • Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital — New Brunswick, New Jersey
  • Newark Beth Israel Medical Center — Newark, New Jersey
  • Saint Joseph's Regional Medical Center — Paterson, New Jersey
Phase 3 Recruiting Network

Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT03550391
Sites in New Jersey:
  • AtlantiCare Surgery Center — Egg Harbor, New Jersey
Phase 3 Recruiting Industry

Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

This is a Phase 3 prospective, randomized, superiority, open-label, multi-site study. The overview of this study is as follows: * A Screening/Baseline Period of 21 days. During this time, patients will be randomized into a 1:2 allocation o…

Sponsor: GT Medical Technologies, Inc.
NCT ID: NCT07195591
Sites in New Jersey:
  • Jersey Shore University Medical Center | Hackensack — Neptune City, New Jersey
Phase 2 Recruiting Network

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …

Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in New Jersey:
  • Hackensack University Medical Center — Hackensack, New Jersey
  • Morristown Medical Center — Morristown, New Jersey
  • Saint Peter's University Hospital — New Brunswick, New Jersey
  • Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital — New Brunswick, New Jersey
  • Newark Beth Israel Medical Center — Newark, New Jersey
Phase 1, Phase 2 Recruiting NIH

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy alone (temozo…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05432804
Sites in New Jersey:
  • Cooperman Barnabas Medical Center — Livingston, New Jersey
  • Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
  • Rutgers New Jersey Medical School — Newark, New Jersey
Phase 2 Recruiting Industry

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…

Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in New Jersey:
  • Overlook Medical Center — Summit, New Jersey
Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase…

Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT04094610
Sites in New Jersey:
  • Local Institution - 2110 — New Brunswick, New Jersey
Phase 2 Recruiting Academic/Other

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

This phase II trial studies how well de-escalating the drugs dabrafenib and trametinib works in treating patients with low-grade gliomas that have a BRAF V600 gene mutation. Dabrafenib and trametinib are in a class of medications called ki…

Sponsor: University of California, San Francisco
NCT ID: NCT07110246
Sites in New Jersey:
  • Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center — Hackensack, New Jersey
Phase 2 Recruiting Academic/Other

A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

The purpose of the study is to see if stereotactic radiosurgery/SRS is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer/SCLC.

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05419076
Sites in New Jersey:
  • Memorial Sloan Kettering at Basking Ridge — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen — Montvale, New Jersey
Phase 2 Recruiting Academic/Other

Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.

Better treatments are needed for high-grade gliomas (HGG), and new ways of treating this disease should be tested. The investigators want to see if giving medicine before radiation works well. After radiation, MRI scans can be harder to un…

Sponsor: The Cooper Health System
NCT ID: NCT07439172
Sites in New Jersey:
  • Cooper University HealthCare — Camden, New Jersey
Phase 1 Recruiting Industry

A Phase 1/1b Study of IAM1363 in HER2 Cancers

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.

Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in New Jersey:
  • Rutgers Cancer Institute — New Brunswick, New Jersey
Phase 1 Recruiting Academic/Other

Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma

The researchers are doing this study to find out whether the drugs ABBV-637 and ABBV-155 are safe treatments that cause few or mild side effects when given alone or in combination with ERAS-801 in people with recurrent GBM.

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06934889
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 1 Recruiting Academic/Other

A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)

The purpose of this study is to find out whether 177Lu-DPTA-omburtamab is a safe treatment for children and adolescents with recurrent/refractory medulloblastoma or another type of cancer with CNS metastases.

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07698899
Sites in New Jersey:
  • Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering at Monmouth (Limited Protocol Activities) — Middletown, New Jersey
  • Memorial Sloan Kettering at Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 1 Recruiting Academic/Other

A Study of 177Lu-PSMA-617 in People With Gliomas

The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type glioma.

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07223034
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in New Jersey:
  • Massive Bio SYNERGY-AI site — New Brunswick, New Jersey
Recruiting Academic/Other

Glioma Developmental and HyperActive Ras Tumor (DHART) Board

This study will collect medical records, scan results, and complete surveys to create a registry about people with a neurofibromatosis type 1-associated brain tumor (NF1-associated glioma). A registry is a collection of health information …

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05489783
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (All protocol activities) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (All Protocol Activities) — Montvale, New Jersey
NA Recruiting Academic/Other

A Study of Stereotactic Radiosurgery (SRS) in People With Brain Cancer Having Tumor Resection Surgery

The researchers are doing this study to see if treating people's brain tumors with stereotactic radiosurgery (SRS) before tumor resection surgery will prevent cancer cells from spreading to other areas of the brain, including the fluid and…

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07802353
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
NA Recruiting Academic/Other

Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

This phase II trial studies the neurological function in patients with multiple brain metastases undergoing stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT). Stereotactic body radiation therapy uses special equ…

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT ID: NCT03184038
Sites in New Jersey:
  • Jefferson Health New Jersey — Sewell, New Jersey

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-12